{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "Liu_et_al.__2024_",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "supports_claim": true,
      "explanation": "The quote directly compares the antibody response induced by the higher-dose recombinant vaccine (RIV4) to that of standard-dose egg-based vaccines (IIV4), showing that RIV4 produced higher neutralizing and binding antibodies against the A (H3 N2) virus. This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' appears in the document, specifically in the first page: 'A (H3 N2) immunogen i city. In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' The wording and factual content are preserved, with only minor formatting differences.",
      "support_explanation": "The quote directly compares the antibody response induced by the higher-dose recombinant vaccine (RIV4) to that of standard-dose egg-based vaccines (IIV4), showing that RIV4 produced higher neutralizing and binding antibodies against the A (H3 N2) virus. This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote directly compares the antibody response induced by the higher-dose recombinant vaccine (RIV4) to that of standard-dose egg-based vaccines (IIV4), showing that RIV4 produced higher neutralizing and binding antibodies against the A (H3 N2) virus, supporting the claim."
    },
    {
      "id": 2,
      "quote": "RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody response in both age groups, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "supports_claim": true,
      "explanation": "The quote explicitly states that RIV4 (the recombinant vaccine) contains three times the hemagglutinin (HA) antigen per dose per strain compared to the standard-dose egg-based (IIV4) and cell-based (ccIIV4) vaccines. It further states that, for A (H3 N2), RIV4 vaccination significantly increased the quantity of total cell HA head binding antibodies, indicating a more robust antibody response. This directly supports the claim that higher-dose recombinant flu vaccine (RIV4) may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote appears on page 9 of the document, though it is split by a line break and some intervening text. The relevant passage is: 'IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody ... years, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).' Earlier in the document, it is stated: 'RIV4 contains 3 times the i d 45 HA/d / ...d' (interpreted as 'RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain)'). The factual content, numbers, and technical details are preserved, though the quote is not contiguous due to formatting.",
      "support_explanation": "The quote explicitly states that RIV4 (the recombinant vaccine) contains three times the hemagglutinin (HA) antigen per dose per strain compared to the standard-dose egg-based (IIV4) and cell-based (ccIIV4) vaccines. It further states that, for A (H3 N2), RIV4 vaccination significantly increased the quantity of total cell HA head binding antibodies, indicating a more robust antibody response. This directly supports the claim that higher-dose recombinant flu vaccine (RIV4) may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote specifies that RIV4 is a higher-dose recombinant vaccine and provides evidence that it leads to a greater quantity of antibody response compared to standard-dose vaccines, directly supporting the claim."
    }
  ],
  "verification_stats": {
    "total_verified": 2
  },
  "image_evidence": [
    {
      "image_filename": "figure_p4_det_3_002.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p4_det_3_002.png",
      "image_type": "Figure",
      "page_number": 4,
      "block_id": "det_3_002",
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "supports_claim": true,
      "explanation": "A multi\u2010panel figure showing microneutralization (MN) and hemagglutination inhibition (HI) antibody titers (log2 scale) against A(H3N2), A(H1N1)pdm09, B/Victoria, and B/Yamagata strains in two age cohorts (18\u201344 and 45\u201364 years), measured against both egg\u2010propagated and cell\u2010propagated viruses at Day 0, 1 month, and 6 months post\u2010vaccination. Four vaccine groups are compared: Fluzone IIV4 (egg\u2010based standard\u2010dose, black), Fluarix IIV4 (egg\u2010based standard\u2010dose, blue), ccIIV4 (cell\u2010based, green), and RIV4 (higher\u2010dose recombinant, orange). Evidence: At 1 month post\u2010vaccination, RIV4 (orange) consistently shows higher GMTs against A(H3N2) than Fluzone IIV4 (black) with statistically significant p\u2010values (e.g., p=0.0008 and p<0.0001 in the 18\u201344 year egg\u2010virus panel; p<0.0001 in the 45\u201364 year cell\u2010virus panel). The data show that the recombinant vaccine (RIV4) induces higher antibody titers than the standard\u2010dose egg\u2010based vaccine with significant p\u2010values, which supports the claim that a higher\u2010dose recombinant flu vaccine may induce a more robust antibody response than egg\u2010based standard\u2010dose vaccines. Note: Comparisons are strongest for A(H3N2); responses to other strains are variable. The figure does not show absolute GMT values or clinical endpoints.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "A multi\u2010panel figure showing microneutralization (MN) and hemagglutination inhibition (HI) antibody titers (log2 scale) against A(H3N2), A(H1N1)pdm09, B/Victoria, and B/Yamagata strains in two age cohorts (18\u201344 and 45\u201364 years), measured against both egg\u2010propagated and cell\u2010propagated viruses at Day 0, 1 month, and 6 months post\u2010vaccination. Four vaccine groups are compared: Fluzone IIV4 (egg\u2010based standard\u2010dose, black), Fluarix IIV4 (egg\u2010based standard\u2010dose, blue), ccIIV4 (cell\u2010based, green), and RIV4 (higher\u2010dose recombinant, orange).",
        "evidence_found": "At 1 month post\u2010vaccination, RIV4 (orange) consistently shows higher GMTs against A(H3N2) than Fluzone IIV4 (black) with statistically significant p\u2010values (e.g., p=0.0008 and p<0.0001 in the 18\u201344 year egg\u2010virus panel; p<0.0001 in the 45\u201364 year cell\u2010virus panel).",
        "reasoning": "The data show that the recombinant vaccine (RIV4) induces higher antibody titers than the standard\u2010dose egg\u2010based vaccine with significant p\u2010values, which supports the claim that a higher\u2010dose recombinant flu vaccine may induce a more robust antibody response than egg\u2010based standard\u2010dose vaccines.",
        "confidence_notes": "Comparisons are strongest for A(H3N2); responses to other strains are variable. The figure does not show absolute GMT values or clinical endpoints."
      }
    },
    {
      "image_filename": "figure_p5_det_4_000.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p5_det_4_000.png",
      "image_type": "Figure",
      "page_number": 5,
      "block_id": "det_4_000",
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "supports_claim": true,
      "explanation": "Scatter plots showing geometric mean fold rise in antibody titers at 1 month post-vaccination (panels A and B) and geometric mean fold reduction from 1 to 6 months post-vaccination (panels C and D) for four vaccines (egg-based Fluzone IIV4, egg-based Fluarix IIV4, cell-based ccIIV4, and recombinant RIV4) across influenza strains (H3N2 egg, H3N2 cell, H1N1 egg, H1N1 cell, B/Victoria egg, B/Victoria cell, B/Yamagata egg, B/Yamagata cell) in two age groups (18\u201344 years and 45\u201364 years). P-values comparing RIV4 to egg-based vaccines are annotated above selected strain comparisons. Evidence: In both age groups, at 1 month post-vaccination (panels A and B), RIV4 (orange) elicited significantly higher geometric mean fold rises in antibody titers than egg-based Fluzone IIV4 and Fluarix IIV4 for H3N2 egg (p<0.0001), H3N2 cell (p<0.0001), H1N1 cell (p=0.021), and additional strains. The data show that the recombinant vaccine (RIV4) induced significantly greater 1-month antibody fold rises compared with egg-based standard-dose vaccines across multiple influenza strains, which supports the claim Note: Image resolution limits precise reading of sample sizes and some p-values; data are limited to ages 18\u201364 and specific strains; fold reduction data at 6 months are not directly relevant to the initial antibody response claim.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Scatter plots showing geometric mean fold rise in antibody titers at 1 month post-vaccination (panels A and B) and geometric mean fold reduction from 1 to 6 months post-vaccination (panels C and D) for four vaccines (egg-based Fluzone IIV4, egg-based Fluarix IIV4, cell-based ccIIV4, and recombinant RIV4) across influenza strains (H3N2 egg, H3N2 cell, H1N1 egg, H1N1 cell, B/Victoria egg, B/Victoria cell, B/Yamagata egg, B/Yamagata cell) in two age groups (18\u201344 years and 45\u201364 years). P-values comparing RIV4 to egg-based vaccines are annotated above selected strain comparisons.",
        "evidence_found": "In both age groups, at 1 month post-vaccination (panels A and B), RIV4 (orange) elicited significantly higher geometric mean fold rises in antibody titers than egg-based Fluzone IIV4 and Fluarix IIV4 for H3N2 egg (p<0.0001), H3N2 cell (p<0.0001), H1N1 cell (p=0.021), and additional strains.",
        "reasoning": "The data show that the recombinant vaccine (RIV4) induced significantly greater 1-month antibody fold rises compared with egg-based standard-dose vaccines across multiple influenza strains, which supports the claim",
        "confidence_notes": "Image resolution limits precise reading of sample sizes and some p-values; data are limited to ages 18\u201364 and specific strains; fold reduction data at 6 months are not directly relevant to the initial antibody response claim."
      }
    },
    {
      "image_filename": "figure_p6_det_5_006.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p6_det_5_006.png",
      "image_type": "Figure",
      "page_number": 6,
      "block_id": "det_5_006",
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "supports_claim": true,
      "explanation": "Multi-panel figure showing ELISA antibody titers (Log2 scale) against egg- and cell-propagated HA antigens from A(H3N2), A(H1N1)pdm09, B/Vic and B/Yam strains at Day 0, 1 month and 6 months post-vaccination (Panel A); geometric mean ratios of egg/cell HA ELISA titers at 1 month for different HA subtypes (Panel B); ELISA titers against H3 and H1 stalk domains over time (Panel C); and fold-rise in stalk ELISA titers at 1 month relative to Day 0 (Panel D). Four vaccine groups are shown: Fluzone IIV4 (egg-based standard dose), Fluarix IIV4 (egg-based standard dose), ccIIV4 (cell-based) and RIV4 (recombinant high-dose). Evidence: At 1 month post-vaccination, the recombinant RIV4 group (orange) exhibits higher ELISA titers against cell-propagated A(H3N2) and A(H1N1)pdm09 HA (Panel A, right) and against H3 and H1 stalk antigens (Panels C and D) compared with the egg-based Fluzone and Fluarix IIV4 groups, with p-values indicating statistical significance. supports the claim because the recombinant high-dose vaccine (RIV4) induces greater binding antibody titers than the egg-based standard-dose vaccines in multiple antigen assays, demonstrating a more robust antibody response. Note: Data are limited to ELISA binding titers and may not reflect functional neutralization; image readability limits extraction of all exact values and full statistical context.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Multi-panel figure showing ELISA antibody titers (Log2 scale) against egg- and cell-propagated HA antigens from A(H3N2), A(H1N1)pdm09, B/Vic and B/Yam strains at Day 0, 1 month and 6 months post-vaccination (Panel A); geometric mean ratios of egg/cell HA ELISA titers at 1 month for different HA subtypes (Panel B); ELISA titers against H3 and H1 stalk domains over time (Panel C); and fold-rise in stalk ELISA titers at 1 month relative to Day 0 (Panel D). Four vaccine groups are shown: Fluzone IIV4 (egg-based standard dose), Fluarix IIV4 (egg-based standard dose), ccIIV4 (cell-based) and RIV4 (recombinant high-dose).",
        "evidence_found": "At 1 month post-vaccination, the recombinant RIV4 group (orange) exhibits higher ELISA titers against cell-propagated A(H3N2) and A(H1N1)pdm09 HA (Panel A, right) and against H3 and H1 stalk antigens (Panels C and D) compared with the egg-based Fluzone and Fluarix IIV4 groups, with p-values indicating statistical significance.",
        "reasoning": "supports the claim because the recombinant high-dose vaccine (RIV4) induces greater binding antibody titers than the egg-based standard-dose vaccines in multiple antigen assays, demonstrating a more robust antibody response.",
        "confidence_notes": "Data are limited to ELISA binding titers and may not reflect functional neutralization; image readability limits extraction of all exact values and full statistical context."
      }
    },
    {
      "image_filename": "figure_p7_mrg_det_6_003.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p7_mrg_det_6_003.png",
      "image_type": "Figure",
      "page_number": 7,
      "block_id": "mrg_det_6_003",
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "supports_claim": true,
      "explanation": "Figure with four panels (A\u2013D) showing immune response metrics to four influenza vaccines (Fluzone IIV4, Fluarix IIV4, ccIIV4, and RIV4) in adults aged 18\u201344 years (panels A and C) and 45\u201364 years (panels B and D). Panels A and B plot the geometric mean ratio of egg-grown to cell-grown virus hemagglutination inhibition titers (95% CI) for each vaccine and strain (A(H3N2), A(H1N1)pdm09, B/VIC, B/YAM). Panels C and D show the proportion of subjects with \u22654-fold lower titers to cell-grown virus pre- and post-vaccination for the same vaccines and strains. Statistical annotations highlight significant differences for the A(H3N2) strain. Evidence: Panel A shows that RIV4 (recombinant vaccine) has a significantly lower egg-to-cell titer ratio for A(H3N2) compared to Fluzone (p=0.0014), Fluarix (p=0.0021), and ccIIV4 (p=0.03) in 18\u201344 year olds. Panel C shows a lower proportion of \u22654-fold reduced titer to cell vaccine virus post-vaccination for A(H3N2) with RIV4 (26%) versus Fluzone (58%), p=0.0001. Similar significant findings are shown in panels B and D for 45\u201364 year olds. The figure supports the claim by demonstrating that the higher-dose recombinant vaccine (RIV4) elicited a more favorable antibody response against cell-grown (wild-type) H3N2 virus compared with egg-based standard-dose vaccines, as evidenced by lower geometric mean egg-to-cell titer ratios and fewer \u22654-fold reduced titers (supports the claim). Note: Findings are limited to the A(H3N2) strain and relative ratios; absolute hemagglutination inhibition titers for each vaccine are not shown, and results may not generalize to other strains or broader clinical efficacy.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Figure with four panels (A\u2013D) showing immune response metrics to four influenza vaccines (Fluzone IIV4, Fluarix IIV4, ccIIV4, and RIV4) in adults aged 18\u201344 years (panels A and C) and 45\u201364 years (panels B and D). Panels A and B plot the geometric mean ratio of egg-grown to cell-grown virus hemagglutination inhibition titers (95% CI) for each vaccine and strain (A(H3N2), A(H1N1)pdm09, B/VIC, B/YAM). Panels C and D show the proportion of subjects with \u22654-fold lower titers to cell-grown virus pre- and post-vaccination for the same vaccines and strains. Statistical annotations highlight significant differences for the A(H3N2) strain.",
        "evidence_found": "Panel A shows that RIV4 (recombinant vaccine) has a significantly lower egg-to-cell titer ratio for A(H3N2) compared to Fluzone (p=0.0014), Fluarix (p=0.0021), and ccIIV4 (p=0.03) in 18\u201344 year olds. Panel C shows a lower proportion of \u22654-fold reduced titer to cell vaccine virus post-vaccination for A(H3N2) with RIV4 (26%) versus Fluzone (58%), p=0.0001. Similar significant findings are shown in panels B and D for 45\u201364 year olds.",
        "reasoning": "The figure supports the claim by demonstrating that the higher-dose recombinant vaccine (RIV4) elicited a more favorable antibody response against cell-grown (wild-type) H3N2 virus compared with egg-based standard-dose vaccines, as evidenced by lower geometric mean egg-to-cell titer ratios and fewer \u22654-fold reduced titers (supports the claim).",
        "confidence_notes": "Findings are limited to the A(H3N2) strain and relative ratios; absolute hemagglutination inhibition titers for each vaccine are not shown, and results may not generalize to other strains or broader clinical efficacy."
      }
    },
    {
      "image_filename": "figure_p8_mrg_det_7_005.png",
      "image_path": "Liu_et_al.__2024_/extracted/figures/figure_p8_mrg_det_7_005.png",
      "image_type": "Figure",
      "page_number": 8,
      "block_id": "mrg_det_7_005",
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "supports_claim": true,
      "explanation": "A multi-panel figure showing hemagglutination inhibition (HI) titers (log\u2082 scale) at Day 0 and 1 month post-vaccination for four influenza strains (A(H3N2), A(H1N1)pdm09, B/Victoria, B/Yamagata). Panels are stratified by age group (18\u201344 yrs and 45\u201364 yrs) and virus source (egg-grown vs cell-grown). Within each panel, boxplots represent six vaccine\u2010sequence groups denoted by color codes (prior season vaccine/current season vaccine: egg-based IIV4, cell-culture ccIIV4, or recombinant RIV4). Statistically significant differences between groups at 1 month are annotated with p-values. Evidence: In the 18\u201344 yrs cell-virus A(H3N2) panel at 1 month, groups receiving recombinant vaccine (RIV4) show significantly higher HI titers than the egg-based IIV4 groups (e.g., p<0.0001, p=0.013, p=0.001, p=0.011). Similar significant increases for RIV4 arms versus IIV4 arms are noted for other strains and age categories. The figure shows vaccine arms that include recombinant RIV4 producing higher antibody titers than egg-based IIV4 at 1 month, with multiple p-values <0.05, which supports the claim that a higher-dose recombinant flu vaccine induces a more robust antibody response than egg-based standard-dose vaccines. Note: Group labels reflect prior/current season combinations; exact numeric titers are not labeled; visual resolution limits precise reading of all p-values and magnitudes; findings pertain to HI titers, not clinical endpoints.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "A multi-panel figure showing hemagglutination inhibition (HI) titers (log\u2082 scale) at Day 0 and 1 month post-vaccination for four influenza strains (A(H3N2), A(H1N1)pdm09, B/Victoria, B/Yamagata). Panels are stratified by age group (18\u201344 yrs and 45\u201364 yrs) and virus source (egg-grown vs cell-grown). Within each panel, boxplots represent six vaccine\u2010sequence groups denoted by color codes (prior season vaccine/current season vaccine: egg-based IIV4, cell-culture ccIIV4, or recombinant RIV4). Statistically significant differences between groups at 1 month are annotated with p-values.",
        "evidence_found": "In the 18\u201344 yrs cell-virus A(H3N2) panel at 1 month, groups receiving recombinant vaccine (RIV4) show significantly higher HI titers than the egg-based IIV4 groups (e.g., p<0.0001, p=0.013, p=0.001, p=0.011). Similar significant increases for RIV4 arms versus IIV4 arms are noted for other strains and age categories.",
        "reasoning": "The figure shows vaccine arms that include recombinant RIV4 producing higher antibody titers than egg-based IIV4 at 1 month, with multiple p-values <0.05, which supports the claim that a higher-dose recombinant flu vaccine induces a more robust antibody response than egg-based standard-dose vaccines.",
        "confidence_notes": "Group labels reflect prior/current season combinations; exact numeric titers are not labeled; visual resolution limits precise reading of all p-values and magnitudes; findings pertain to HI titers, not clinical endpoints."
      }
    }
  ]
}